1. CARD14 ‐associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature
- Author
-
Amy S. Paller, Cindy P. Frare, Alli J. Blumstein, Lia Pieretti, Keith A. Choate, Anne M. Bowcock, and Margarita Larralde
- Subjects
medicine.medical_specialty ,Response to therapy ,business.industry ,Membrane Proteins ,Autosomal dominant trait ,Dermatology ,Disease ,Exanthema ,medicine.disease ,Article ,CARD Signaling Adaptor Proteins ,Guanylate Cyclase ,Cape ,Psoriasis ,Pityriasis Rubra Pilaris ,Pediatrics, Perinatology and Child Health ,Ustekinumab ,medicine ,Humans ,Pityriasis rubra pilaris ,Family history ,Child ,business ,medicine.drug - Abstract
CARD14-associated papulosquamous eruption (CAPE) is a proposed term that encompasses features ranging from psoriasis to pityriasis rubra pilaris (PRP) in association with CARD14 mutations. The early onset of the disease, prominent facial involvement, family history of an autosomal dominant trait, and poor response to conventional treatment are characteristics of CAPE that distinguish it from classical psoriasis and PRP. We describe the clinical features, family history, and response to therapy in three unrelated children with CAPE and compare these characteristics with those of previously described pediatric patients. Testing for CARD14 mutations in children with early onset of features of psoriasis or pityriasis rubra pilaris and resistance to conventional therapy should be considered.
- Published
- 2021
- Full Text
- View/download PDF